PODD Stock Analysis: Buy, Sell, or Hold?
PODD - Insulet Corporation
$148.16
1.29 (0.88%)
â˛
5d:
+3.36%
30d:
-6.45%
90d:
-5.56%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When PODD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PODD is fairly priced but lacks strong directional signals. At -13.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PODD is fairly priced but lacks strong directional signals. At -13.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$327.48
Based on 11.3% avg growth
INTRINSIC VALUE TODAY
$203.34
27.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PODD is currently trading at $148.16, which is considered fair relative to its 30-day fair value range of $144.88 to $166.95. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.2) compared to its historical average (29.6). Remarkably, the market is currently pricing in an annual earnings decline of 13.4% over the next few years. This pessimistic expectation contrasts with the company's recent 328.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PODD is in a strong downtrend. Immediate support is located at $138.28, while resistance sits at $155.17.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $171.91 (+16.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PODD is in a strong downtrend. Immediate support is located at $138.28, while resistance sits at $155.17.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $171.91 (+16.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$144.88 -
$166.95
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
Protect Your Profits
Holding PODD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($171.91)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$144.88 -
$166.95
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$138.28
Resistance Level
$155.17
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.21
Wall Street Target
$171.91
(+16.0%)
Revenue Growth (YoY)
23.5%
Earnings Growth (YoY)
328.6%
Profit Margin
12.3%
Valuation Discount vs History
-13.4% cheaper
PE vs Historical
19.2 vs 29.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.4%
(market-implied from PE analysis)
1-Year Target
$133.34
(-10%)
2-Year Target
$120.01
(-19%)
3-Year Target
$108.01
(-27%)
3-Yr Target (if PE normalizes)
(PE: 19â30)
$166.39
(+12%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 18.6%)
$258.02
(+74%)
Base:
(SPY PE: 19.2, Growth: 18.6%)
$247.02
(+67%)
Bear:
(PE: 16.3, Growth: 18.6%)
$209.96
(+42%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 28.41 | Current EPS (TTM): $5.17
Bull Case
$240.96
(+63%)
Analyst growth 49.1%, PE expands to 31.3
Base Case
$219.05
(+48%)
Market implied 49.1%, PE stable at 28.4
Bear Case
$99.87
(-33%)
Severe decline -20.0%, PE contracts to 24.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.2 to 29.6
Stabilization Target:
$228.24
(+54.1%)
PE Expansion Potential:
+54.1%
Share & Embed Analysis
Last updated: August 24, 2026 1:35 AM ET
Data refreshes hourly during market hours. Next update: 2:35 AM
Data refreshes hourly during market hours. Next update: 2:35 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PODD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
Advanced PODD Option Strategies
Professional options setups generated by AI based on today's PODD price and gamma walls.
